default author photo

Taishi Harada

affiliation not provided to SSRN

  • affiliation not provided to SSRN

SCHOLARLY PAPERS

5

DOWNLOADS

256

TOTAL CITATIONS

0

Scholarly Papers (5)

Actions:
Email selected abstracts
1.

Atezolizumab with Carboplatin Plus Nab-Paclitaxel Combination Therapy for TTF-1 Negative Advanced Nonsquamous Non–Small Cell Lung Cancer: A Multicenter, Single-Arm Phase 2 Trial (F1NE TUNE, LOGiK 2102)

Number of pages: 22 Posted: 16 Jul 2025
Yoshimasa Shiraishi, Takayuki Shimose, Motoko Tachihara, Yuko Tsuchiya-Kawano, Ryotaro Morinaga, Hiroyuki Inoue, Yukihiro Toi, Tadaaki Yamada, Masafumi Yamaguchi, Kosuke Kashiwabara, Kazunori Tobino, Hidenobu Ishii, Yoshihiko Sakata, Megumi Inaba, Kazuhisa Nakashima, Kenji Chibana, Tomoya Fukui, Miiru Izumi, Ryota Saito, Hiroshi Ishii, Shota Omori, Shinsuke Ogusu, Kazuto Furuyama, Satoru Miura, Taishi Harada and Isamu Okamoto
Kyushu University, affiliation not provided to SSRN, Kobe University, Kitakyushu Municipal Medical Center, affiliation not provided to SSRN, affiliation not provided to SSRN, Sendai Kousei Hospital, Kyoto Prefectural University of Medicine, affiliation not provided to SSRN, Kumamoto Regional Medical Center - Department of Respiratory Medicine, Iizuka Hospital, Kurume University - Kurume University Hospital, Saiseikai Kumamoto Hospital, Kumamoto Chuo Hospital, affiliation not provided to SSRN, affiliation not provided to SSRN, Shonan Kamakura General Hospital, affiliation not provided to SSRN, Tohoku University - Tohoku University Hospital, Fukuoka University Chikushi Hospital, affiliation not provided to SSRN, Saga University, affiliation not provided to SSRN, Niigata Cancer Center Hospital, affiliation not provided to SSRN and Kyushu University - Kyushu University Hospital
Downloads 145 (521,245)

Abstract:

Loading...

Immune checkpoint inhibitor, Atezolizumab, Carboplatin, nab-paclitaxel, Nonsquamous non-small cell lung cancer

2.

Biological Impact of Chemotherapy During Treatment with Egfr Tyrosine Kinase Inhibitors for Non-Small Cell Lung Cancer Positive for Egfr Activating Mutations

Number of pages: 24 Posted: 11 Apr 2025
Eiji Iwama, Kazuko Sakai, Taishi Harada, Shintaro Kanda, Shunichi Sugawara, Toshihide Yokoyama, Hirokazu Taniguchi, Kaoru Tanaka, Ryo Toyozawa, Kenichi Koyama, Yoshitaka Zenke, Gen Kida, Yasuhiko Nishioka, Hiroshi Yokouchi, Masayuki Hirose, Kazuto Nishio, Nobuyuki Yamamoto, Yuichiro Ohe and Isamu Okamoto
Kyushu University - Kyushu University Hospital, Kindai University - Kindai University Hospital, affiliation not provided to SSRN, Shinshu University - Department of Hematology and Medical Oncology, Sendai Kousei Hospital - Department of Pulmonary Medicine, Kurashiki Central Hospital - Department of Respiratory Medicine, Nagasaki University, Kindai University, National Hospital Organization Kyushu Cancer Center, Niigata Cancer Center Hospital, National Cancer Center Hospital East, Saitama Cancer Center, Tokushima University, National Hospital Organization Hokkaido Medical Center, Kyushu University - Kyushu University Hospital, Kindai University, Wakayama Medical University - Department of Pulmonary Medicine and Medical Oncology, National Cancer Center Hospital and Kyushu University - Kyushu University Hospital
Downloads 34 (1,277,121)

Abstract:

Loading...

Epidermal growth factor receptor (EGFR), Tyrosine kinase inhibitor, Circulating tumor DNA, chemotherapy, Osimertinib

3.

Pemetrexed Plus Platinum as Second-Line Treatment for Patients with Pleural Mesothelioma Treated with Nivolumab Plus Ipilimumab

Number of pages: 26 Posted: 08 Apr 2025
Sawana Ono, Hirokazu Taniguchi, Koji Kuroda, Teppei Hashimoto, Asuka Okada, Yasuhiro Goto, Hidenori Kitai, Yoichi Nakamura, Shinsuke Ogusu, Tetsunari Hase, Takayo Ota, Noriyuki Ebi, Makoto Furugen, Taishi Harada, Yoshiaki Kinoshita, Takaki Mizoguchi, Katsumi Nakatomi, Yoshifumi Soejima, Takahiro Yamada, Shinnosuke Takemoto and Hiroshi Mukae
affiliation not provided to SSRN, Nagasaki University, University of Occupational and Environmental Health, University of Occupational and Environmental Health, Osaka City General Hospital, Fujita Health University, Hokkaido University, affiliation not provided to SSRN, Saga University, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, University of the Ryukyus, affiliation not provided to SSRN, Fukuoka University Chikushi Hospital, Kanazawa Medical University, National Hospital Organization Ureshino Medical Center, affiliation not provided to SSRN, affiliation not provided to SSRN, Nagasaki University and Nagasaki University - Department of Respiratory Medicine
Downloads 34 (1,277,121)

Abstract:

Loading...

Mesothelioma, Chemotherapy, Pemetrexed, Platinum, Second-line

4.

Biological Impact of Chemotherapy During Treatment with Egfr Tyrosine Kinase Inhibitors for Non-Small Cell Lung Cancer Positive for Egfr Activating Mutations

Number of pages: 22 Posted: 11 Jul 2025
Eiji Iwama, Kazuko Sakai, Taishi Harada, Shintaro Kanda, Shunichi Sugawara, Toshihide Yokoyama, Hirokazu Taniguchi, Kaoru Tanaka, Ryo Toyozawa, Kenichi Koyama, Yoshitaka Zenke, Gen Kida, Yasuhiko Nishioka, Hiroshi Yokouchi, Masayuki Hirose, Kazuto Nishio, Yuichiro Ohe, Nobuyuki Yamamoto and Isamu Okamoto
Kyushu University - Kyushu University Hospital, Kindai University - Kindai University Hospital, affiliation not provided to SSRN, Shinshu University - Department of Hematology and Medical Oncology, Sendai Kousei Hospital - Department of Pulmonary Medicine, Kurashiki Central Hospital - Department of Respiratory Medicine, Nagasaki University, Kindai University, National Hospital Organization Kyushu Cancer Center, Niigata Cancer Center Hospital, National Cancer Center Hospital East, Saitama Cancer Center, Tokushima University, National Hospital Organization Hokkaido Medical Center, Kyushu University - Kyushu University Hospital, Kindai University, National Cancer Center Hospital, Wakayama Medical University - Department of Pulmonary Medicine and Medical Oncology and Kyushu University - Kyushu University Hospital
Downloads 23 (1,424,331)

Abstract:

Loading...

Epidermal growth factor receptor (EGFR), tyrosine kinase inhibitor, Circulating tumor DNA, chemotherapy, Osimertinib

5.

Tumor size assessment for prediction of osimertinib efficacy in EGFR-mutated non–small cell lung cancer

Number of pages: 20 Posted: 24 Dec 2025
Tomonobu Nagase, Eiji Iwama, Hiroaki Ogata, Yuki Ikematsu, Daisuke Shibahara, Kohei Otsubo, Yoshimasa Shiraishi, Taishi Harada and Isamu Okamoto
Kyushu University, Kyushu University - Kyushu University Hospital, Kyushu University, Kyushu University, Kyushu University, Kyushu University - Kyushu University Hospital, Kyushu University, affiliation not provided to SSRN and Kyushu University - Kyushu University Hospital
Downloads 20 (1,459,862)

Abstract:

Loading...

Epidermal growth factor receptor (EGFR)Tyrosine kinase inhibitorOsimertinibTumor sizePrimary lesion